Hansoh Pharmaceutical announced positive Phase III results from its ARTEMIS-008 study in China for small-cell lung cancer, a major research milestone for its licensor position of GSK’s investigational therapy (Ris-Rez). The company framed the results as a key step forward in the clinical program, supporting a favorable outlook for the asset’s development pathway.
Hansoh Pharmaceutical announced positive Phase III results from its ARTEMIS-008 study in China for small-cell lung cancer, a major research milestone for its licensor position of GSK’s investigational therapy (Ris-Rez). The company framed the results as a key step forward in the clinical program, supporting a favorable outlook for the asset’s development pathway.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
